Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
October 18, 2019

FDA approves Roche’s Xofluza for patients at high risk of developing flu-related complications

Roche has secured approval from the US Food and Drug Administration (FDA) for its Xofluza (baloxavir marboxil) to treat people at high risk of developing influenza-related complications.

Image: Image: Site Roche Basel. Photo: courtesy of F. Hoffmann-La Roche Ltd.